3 completed, 1 recruiting, 1 terminated. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Sickle Cell Disease (SCD): new trials by email Literature Review of Sickle Cell Disease (SCD) trials Research Report on Sickle Cell Disease (SCD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD) | Phase 2 / Phase 3 | Recruiting | Yves Pastore | 29 | 2026-02-03 | 2026-08-21 |
| Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease ALXN1820 - Sickle Cell Disease (SCD) | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 2 | 2023-02-22 | 2025-01-13 |
| Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease Crizanlizuamb, Standard of Care - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 58 | 2019-12-10 | 2024-10-09 |
| Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients Crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 117 | 2018-10-01 | 2025-10-16 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2017-12-19 | 2024-10-09 |
Anemia, Sickle Cell (5) · Albuminuria (1) · COVID-19 (1) · Hemoglobin SC Disease (1) · Renal Insufficiency, Chronic (1) · Vaso-Occlusive Crises (1)
Anemia (5) · Anemia, Hemolytic (5) · Anemia, Hemolytic, Congenital (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Hemoglobinopathies (5) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Infections (1)
crizanlizumab (2) · Standard of Care (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (1) · Yves Pastore (1)
United States (4) · Brazil (2) · Canada (2) · France (2) · Lebanon (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Belgium (1) · Colombia (1) · Germany (1) · Greece (1) · India (1) · Ireland (1) · Italy (1)
PMID 34922648, PMID 36355805, PMID 36529836, PMID 37254256, PMID 39497751, PMID 40569673
2017 (1), 2018 (1)